Eisai Australia

 

 

 

 

Eisai Australia

human health care

 

About

Eisai Co., Ld. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy.

With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realise our hhc philosophy by delivering innovative products in multiple therapeutic areas with high unmet medical needs, including Oncology and Neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries

Products

HALAVEN (eribulin mesilate) is a first-in-class halichondrin B-based, microtubule dynamics inhibitor. It is a structurally simplified synthetic analogue of halichondrin B, a natural product isolated from the marine sponge Halichondria okadai.

Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into non-productive aggregates. Eribulin exerts its effects via a tubulin-based antimitotic mechanism leading to G2/M cell-cycle block, disruption of mitotic spindles and, ultimately, apoptotic cell death after prolonged and irreversible mitotic blockage.

Eribulin also affects the tumour microenvironment and tumour phenotype by mechanisms that are not linked to its antimitotic effects. These additional effects of eribulin include: (i) tumour vasculature remodelling whereby inner tumour cores become better perfused and less hypoxic, and (ii) phenotypic shifts from more aggressive mesenchymal phenotypes to less aggressive epithelial phenotypes via reversal of the epithelial-mesenchymal transition (EMT).

Connect

Eisai Australia
PO Box 33004
Melbourne
VICTORIA 3004

General enquires telephone number: +61 3 9832 9100
Website: www.eisai.com.au
Email: contact_australia@eisai.net